博汇股份 reported revenue of ¥2.05B for the period ended 2026-06-30, +53.1% year on year. Net income was ¥0.02B, a 0.9% net margin on a 11.8% gross margin. The largest revenue line is 销售商品 at 97% of the total. Free cash flow for the period was ¥-0.10B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.05B | +53.1% |
| Gross profit | ¥0.24B | — |
| Operating income | ¥0.03B | — |
| Net income | ¥0.02B | — |
| Gross margin | 11.8% | Net margin 0.9% |
| Revenue Q/Q | +20.9% | — |
| Segment | Revenue | Share |
|---|---|---|
| 销售商品 | ¥2.00B | 97.4% |
| 提供服务 | ¥0.05B | 2.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.81B | 88.2% |
| R&D | ¥0.01B | 0.3% |
| SG&A | ¥0.02B | 1.1% |
| Tax & other | ¥0.01B | 0.5% |
| Item | Amount |
|---|---|
| Total assets | ¥2.22B |
| Total liabilities | ¥1.44B |
| Shareholders' equity | ¥0.78B |
| Equity / assets | 35.1% |
| Operating cash flow | ¥-0.10B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.10B |
| Cash conversion (OCF / net income) | -311% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
酷特智能 ・ 康华生物 ・ 帝科股份 ・ 胜蓝股份 ・ 山水比德 ・ 捷安高科 ・ 首都在线 ・ 中船汉光 ・ 美瑞新材 ・ 锦盛新材 ・ 新强联 ・ 交大思诺
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies